Summary of Key Points
On August 24th, Roche, through its subsidiary Genentech, reached an agreement with South Korean company Hanmi Pharmaceutical for up to $2.3 billion, acquiring the global rights to a weight-loss drug called HM17321 (excluding South Korea). The most significant feature of this drug is its ability to reduce fat while preserving or even increasing muscle mass, which addresses the common issue with current mainstream GLP-1 class weight-loss drugs (such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound), which tend to cause muscle loss. Roche’s goal is to become one of the top three players in the global obesity market. This collaboration fills a gap in its portfolio with a non-GLP-1 mechanism, although the new drug is still in the early stages of clinical development and faces numerous challenges, including research and development and competition.
Detailed Analysis
1. The New Drug HM17321: Targeting the “Muscle Loss” Problem of Existing Weight-Loss Drugs
While popular GLP-1 class weight-loss drugs can significantly reduce weight, they have a significant drawback: a large portion of the lost weight is muscle mass (referred to as “lean body mass”). A decrease in muscle mass can slow down metabolism, lead to weight rebound, and even affect physical strength. HM17321 is designed to address this issue:
- Unique Mechanism: It acts as a “uricosterone-2 analog,” activating the CRF2 receptor in the body, which is a completely different pathway from GLP-1.
- Preliminary Efficacy: Animal studies have shown that it can reduce fat and preserve muscle, whether used alone or in combination with GLP-1.
- Current Stage: The drug is in Phase I clinical trials (testing safety and dosage), with Hanmi Pharmaceutical leading the Phase I trials and Roche taking over Phase II and subsequent development.
In short, this drug aims to help people lose weight in a healthier way, focusing on reducing fat while maintaining muscle.
2. Roche’s Ambitions in the Obesity Market: To Become One of the Top Three Players
Roche has previously had a limited presence in the obesity market but is now aggressively competing with Eli Lilly and Novo Nordisk, the leaders in the GLP-1 class. To achieve its goal of becoming one of the top three, Roche has made several moves:
- December 2023: Acquired Carmot for $2.7 billion to gain access to GLP-1/GIP dual-target drugs (such as CT-388, planned for market release in 2030).
- March 2025: Collaborated with Zealand to develop a long-acting analog of glucagon-like peptide (GLP-1) that is effective and safe for weight loss.
- Also has an internal muscle-building antibody (emugrobart) in combination with Eli Lilly’s Mounjaro for testing.
- The acquisition of HM17321 complements its portfolio with a non-GLP-1 mechanism, providing a more comprehensive range of weight-loss options.
Roche’s strategy is to use a combination of drugs with different mechanisms to meet the needs of a wider range of patients and compete with Eli Lilly and Novo Nordisk, which already dominate the market.
3. The Shift in the Weight-Loss Industry: From Focusing on Weight to Focusing on Body Composition
In the past, weight loss was measured solely by the number of pounds lost. Now, the industry is paying more attention to the composition of the body. Muscle is essential for metabolism, and weight loss methods that deplete muscle are unhealthy and prone to rebound.
- Why This Is Important: For example, if two people lose 10 pounds, one may lose 5 pounds of fat and 5 pounds of muscle, while the other loses 8 pounds of fat and 2 pounds of muscle. The latter option is healthier and less likely to result in weight rebound.
- Other Players: In addition to Hanmi Pharmaceutical, Danish company Gubra is developing a similar UCN2 drug (GUB-UCN2), which has already started Phase I/IIa trials.
The concept of “fat loss while preserving muscle” is becoming the new standard for weight-loss drugs. Future drugs will not only need to reduce weight but also ensure that the weight loss is of high quality.
4. Roche’s Challenges
Despite its aggressive moves, Roche still faces many challenges:
- Research and Development Risks: HM17321 is still in Phase I, and the results from animal studies may not be replicated in humans. It will need to go through Phase II (efficacy) and Phase III (large-scale validation) before it can be marketed, which could take another 5-10 years.
- Competitive Pressure: Eli Lilly and Novo Nordisk control a large portion of the market with annual sales in the billions of dollars. Roche’s new drugs must demonstrate that they are superior in reducing fat and preserving muscle to attract doctors and patients.
- Integration Challenges: Some of the assets acquired from Carmot have been terminated, and Roche needs to manage multiple drugs with different mechanisms efficiently to avoid waste.
However, Roche has advantages, such as its diagnostic capabilities that can help identify the most suitable patients for certain drugs, and its cardiovascular and metabolic drug pipelines that can be combined with weight-loss treatments, potentially giving it a competitive edge.
5. The Future of “Fat Loss While Preserving Muscle”
Whether “fat loss while preserving muscle” becomes the mainstream depends on two factors:
- Clinical Data from New Drugs: If clinical trials prove that these drugs are effective and safe, they could revolutionize obesity treatment, with doctors considering both weight and muscle changes when prescribing weight-loss drugs.
- Roche’s Execution: Whether Roche can successfully integrate its portfolio and bring these drugs to market quickly. Eli Lilly and Novo Nordisk will also be working on similar technologies.
In summary, Roche’s investment in HM17321 represents a bet on the next generation of weight-loss therapies. Whether this strategy will be successful will depend on clinical results and market feedback over the coming years.
In One Sentence
Roche has made a significant investment in a weight-loss drug that preserves muscle mass, aiming to gain a share of the obesity market. However, the road ahead is long, as it must prove the effectiveness of the new drug and compete with market leaders. This shift towards healthier weight loss methods suggests that weight loss will no longer be simply about reducing overall weight but also about maintaining healthy body composition.